U.S. Patent 5,846,976: Dutasteride Method-of-Use Claims, Scope, Expiration, and Patent Landscape

U.S. Patent No. 5,846,976 covered methods of treating androgen-responsive conditions with dutasteride, including benign prostatic hyperplasia, prostate cancer, acne, male pattern baldness, and hirsutism. It also covered pharmaceutical formulations containing dutasteride alone or combined with an alpha-1 adrenergic blocker, tamoxifen, clomiphene, or flutamide. The patent was listed for Avodart, but its Orange Book patent term ended on June 19, 2016. It no longer creates an enforceable barrier to FDA-approved dutasteride generic entry.[1]

What compound does U.S. Patent 5,846,976 cover?

The compound identified in the claims is dutasteride, also known as:

17β-N-(2,5-bis(trifluoromethyl)phenylcarbamoyl)-4-aza-5α-androst-1-en-3-one
GI198745
The active ingredient in Avodart
A dual 5-alpha-reductase inhibitor targeting Type 1 and Type 2 5-alpha-reductase

The patent does not claim dutasteride as a composition of matter in the claims supplied. It claims therapeutic use of dutasteride and specified formulations containing dutasteride.

Dutasteride inhibits conversion of testosterone to dihydrotestosterone, or DHT. The mechanism supports treatment of androgen-mediated conditions, particularly benign prostatic hyperplasia and androgenic alopecia.

What are the claims of U.S. Patent 5,846,976?

The claims divide into two groups: direct treatment claims and formulation or combination-treatment claims.

Claim	Core subject matter	Scope
1	Treatment of an androgen-responsive or androgen-mediated condition with dutasteride or a pharmaceutically acceptable solvate	Principal method claim
2	Claim 1 limited to BPH, prostate cancer, acne, male pattern baldness, or hirsutism	Enumerated indications
3	Treatment using a pharmaceutical formulation containing dutasteride or a solvate	Formulation-based method claim
4	Claim 3 with an alpha-1 adrenergic receptor blocker	Combination formulation
5	Claim 3 with clomiphene or tamoxifen	Anti-estrogen combination
6	Claim 5 limited to tamoxifen	Narrower anti-estrogen claim
7	Claim 3 with an anti-androgen	Combination formulation
8	Claim 6 with flutamide	Dutasteride, tamoxifen, and flutamide combination

How broad is claim 1?

Claim 1 is broad in disease coverage but narrow in active-ingredient identity. It requires:

A mammalian patient;
An androgen-responsive or androgen-mediated condition;
Administration of a safe and effective amount;
Dutasteride or a pharmaceutically acceptable solvate.

The claim does not limit the dosage form, route of administration, dosing schedule, disease severity, treatment duration, or particular patient subgroup. Its principal limitation is the requirement to use the specifically identified dutasteride molecule.

The phrase “androgen responsive or mediated condition” supplies a broad functional category. Claim 2 narrows that category by listing five conditions. Because claim 2 depends on claim 1, it retains all limitations of claim 1.

What does “pharmaceutically acceptable solvate” add?

The solvate language extends claim coverage beyond an unsolvated form of dutasteride to pharmaceutically acceptable solvated forms. The scope would depend on whether the particular solvate was chemically and pharmaceutically acceptable and whether its administration fell within the claimed treatment method.

The solvate limitation does not automatically cover every salt, polymorph, hydrate, prodrug, metabolite, or derivative. Those forms would require analysis under the claim language, prosecution history, and potentially the doctrine of equivalents.

What formulations are protected by U.S. Patent 5,846,976?

Claim 3 covers a pharmaceutical formulation containing dutasteride or an acceptable solvate when that formulation is administered to treat an androgen-responsive or androgen-mediated condition.

The claim is not limited to Avodart’s commercial capsule composition. It does not recite specific excipients, dissolution characteristics, particle size, capsule shell, release profile, or manufacturing parameters. As a result, the formulation claim is functional and potentially covers multiple dosage forms, provided the formulation contains dutasteride and is used in the claimed treatment method.

Are Avodart capsules specifically claimed?

The supplied claims do not expressly claim:

A 0.5 mg dutasteride capsule;
A particular gelatin capsule;
Specific inactive ingredients;
A defined dissolution profile;
A sustained-release or modified-release dosage form;
A particular manufacturing process.

Avodart’s commercial product was a 0.5 mg dutasteride soft gelatin capsule. The patent’s formulation claims could reach such a product when used for the claimed indications, but the claims do not appear limited to the commercial formulation.

What combination products are covered?

The dependent claims target combination use:

Claim 4: dutasteride plus an alpha-1 adrenergic receptor blocker;
Claim 5: dutasteride plus clomiphene or tamoxifen;
Claim 6: dutasteride plus tamoxifen;
Claim 7: dutasteride plus an anti-androgen;
Claim 8: dutasteride plus tamoxifen and flutamide.

Claim 4 is particularly relevant to BPH because alpha-1 blockers such as tamsulosin relax prostatic and bladder-neck smooth muscle, while dutasteride reduces DHT-driven prostate growth. The later Avodart/tamsulosin product Jalyn used tamsulosin, but the supplied claim does not expressly identify tamsulosin.

Claim 8 is structurally narrow. Because it depends on claim 6, it requires the formulation to include tamoxifen, and it further requires flutamide as the anti-androgen. It is not a general claim to dutasteride combined with any anti-androgen.

When did U.S. Patent 5,846,976 expire?

The patent’s Orange Book-listed expiration date was June 19, 2016.[1] The patent issued on December 8, 1998, but the effective patent term was governed by the applicable patent-term rules and related patent-family treatment rather than simply by the issue date.[2]

Event	Date or status
U.S. patent application and prosecution	1990s
Patent issued	December 8, 1998
Avodart NDA approval	November 20, 2001
New chemical entity exclusivity	Ended in November 2006
Orange Book patent expiration	June 19, 2016
Current status	Expired

The FDA’s regulatory exclusivity and the patent term were separate rights. Avodart’s five-year new chemical entity exclusivity expired before the listed patent expiration date. After NCE exclusivity ended, ANDA applicants could rely on the reference product’s safety and efficacy findings, subject to patent certification requirements.

What was the Orange Book status of U.S. Patent 5,846,976?

U.S. Patent 5,846,976 was historically listed in the FDA Orange Book for Avodart, a dutasteride product marketed by GlaxoSmithKline.[1] The listing identified a method-of-use patent rather than a basic chemical composition patent.

Historically associated Avodart patent listings included:

Patent	General category	Historical expiration listed for Avodart
U.S. 5,565,467	Dutasteride-related composition or compound protection	June 19, 2016
U.S. 5,846,976	Dutasteride method-of-use protection	June 19, 2016
U.S. 6,197,812	Dutasteride formulation or use-related protection	June 19, 2016
U.S. 6,844,410	Later dutasteride-related protection	June 19, 2016

The exact legal effect of each listing depended on the claims of the particular patent and the applicant’s proposed labeling. An Orange Book listing did not establish that every claim would be infringed by every dutasteride product.

How did Paragraph IV challenges affect dutasteride generic entry?

An ANDA applicant seeking approval before patent expiration could submit a Paragraph IV certification asserting that a listed patent was invalid, unenforceable, or would not be infringed. The certification could trigger patent litigation under the Hatch-Waxman Act.[3]

For dutasteride, the commercial entry analysis focused on:

Whether the applicant’s label included patented indications;
Whether the proposed product included the claimed active ingredient and formulation;
Whether the applicant could use a section viii statement to carve out patented uses;
Whether the applicant accepted a delayed launch through settlement;
Whether the listed patents had already expired by the time of FDA approval.

Because the key Avodart patent listings expired in June 2016, the practical value of Paragraph IV litigation declined sharply after that date. Generic applicants could enter without overcoming an unexpired listed patent, subject to ordinary FDA approval requirements and any separate non-patent regulatory barriers.

Which companies challenged the Avodart patent estate?

Public generic competition involved major ANDA companies, including Teva and other manufacturers seeking approval for dutasteride capsules. The relevant disputes concerned the broader Avodart patent estate rather than U.S. Patent 5,846,976 alone.

The litigation risk assessment for an ANDA applicant depended on whether the applicant:

Challenged all relevant listed patents;
Filed a section viii carve-out for protected indications;
Sought approval only after patent expiration;
Entered into a settlement permitting a defined launch date.

After expiration, the litigation question shifted from blocking generic approval to potential damages, launch timing, and settlement interpretation. Expiration eliminated prospective infringement remedies for conduct occurring after the statutory term.

What is the litigation status of U.S. Patent 5,846,976?

U.S. Patent 5,846,976 is expired. An expired patent cannot support an injunction against current dutasteride sales based on post-expiration conduct. Any historical litigation involving the patent would be relevant to past damages, settlement obligations, or claim interpretation, but it does not create current exclusivity.

The supplied claims also present several potential litigation issues that would have mattered before expiration:

Infringement issues

A plaintiff would have needed to establish that the accused product or use satisfied each limitation, including:

Administration to a mammal;
Treatment of an androgen-responsive or androgen-mediated condition;
A safe and effective amount;
Dutasteride or an acceptable solvate;
For dependent claims, the specified co-ingredient or combination.

A generic manufacturer selling dutasteride under a label limited to non-patented uses could have reduced method-of-use exposure. The analysis would depend on the actual label, promotional conduct, physician instructions, and evidence of induced infringement.

Validity issues

Potential validity issues would have included:

Written description and enablement for the breadth of “androgen responsive or mediated condition”;
Obviousness based on prior anti-androgen and 5-alpha-reductase inhibitor research;
Definiteness of the functional disease category;
Support for the claimed combination formulations;
Patent-term and terminal-disclaimer issues involving related patents.

Because the patent has expired, these issues no longer affect current market exclusivity.

How strong was the patent estate for dutasteride?

The overall dutasteride estate was stronger than U.S. Patent 5,846,976 considered alone because it included multiple patents directed to different protection layers.

Protection layer	Relevance
Chemical composition	Protects dutasteride itself and limits direct copy products
Method of treatment	Covers use in BPH and other androgen-mediated conditions
Formulation	May cover dosage forms, excipients, or delivery characteristics
Combination therapy	Covers dutasteride with specified complementary agents
Manufacturing process	Can create barriers if the process is necessary or commercially preferred
Regulatory exclusivity	Delays reliance on the reference product even without patent infringement

Patent 5,846,976 was commercially important because it connected dutasteride to therapeutic use. Its weakness was that it did not provide indefinite composition-of-matter protection and did not recite detailed formulation limitations in the supplied claims. Once the core composition and related Orange Book patents expired, generic manufacturers could compete through the ANDA pathway.

What generic entry risks exist for dutasteride?

Dutasteride is a small-molecule drug, so biosimilar regulation does not apply. Generic manufacturers use the ANDA pathway rather than the biosimilar pathway.[4]

Current commercial risks are concentrated in ordinary generic competition:

Multiple approved dutasteride capsule suppliers;
Price erosion in the 0.5 mg capsule market;
Substitution through pharmacy benefit plans;
Competition from finasteride and combination therapy;
Competition from tamsulosin/dutasteride products such as Jalyn;
Possible manufacturing or supply-chain interruptions;
State and federal requirements governing generic substitution.

The patent estate does not present a current blocking risk from Patent 5,846,976.

How does dutasteride patent protection compare with finasteride?

Dutasteride and finasteride are both 5-alpha-reductase inhibitors, but their patent positions developed differently.

Issue	Dutasteride	Finasteride
Primary brand	Avodart	Proscar and Propecia
Target	Type 1 and Type 2 5-alpha-reductase	Primarily Type 2
BPH use	Yes	Yes
Hair-loss use	Not the principal FDA-approved Avodart indication	Propecia approved for male pattern hair loss
Patent 5,846,976	Dutasteride method-of-use claims	Not applicable
Biosimilar pathway	Not applicable	Not applicable
Current market structure	Generic competition	Generic competition

Dutasteride’s broad androgen-mediated disease language was commercially wider than its principal FDA-approved BPH positioning. That difference created potential method-of-use questions but did not preserve market exclusivity after patent expiration.

What licensing deals affected dutasteride?

The core dutasteride program was developed and commercialized within the Glaxo/GlaxoWellcome and later GlaxoSmithKline organization. The central commercial products were Avodart and, later, the dutasteride/tamsulosin combination product Jalyn.

No current licensing arrangement can revive the expired exclusionary rights in U.S. Patent 5,846,976. Any license tied specifically to that patent would now have value only for historical claims, settlement rights, or contractual obligations that survived expiration. A license to separate, unexpired know-how, manufacturing rights, trademarks, or regulatory assets would require independent analysis.

What geographic coverage did U.S. Patent 5,846,976 provide?

The patent provided rights only in the United States. Parallel foreign patents may have covered dutasteride compounds, formulations, or therapeutic uses in Europe, Canada, Japan, and other jurisdictions, but expiration dates and claim scope varied by country.

U.S. patent expiration did not automatically terminate foreign rights. Conversely, a surviving foreign patent could not block sales, manufacture, or use occurring solely in the United States.

Key Takeaways

U.S. Patent 5,846,976 claimed methods of treating androgen-mediated conditions with dutasteride.
Claim 2 identified BPH, prostate cancer, acne, male pattern baldness, and hirsutism.
Claims 3 through 8 covered dutasteride formulations and specified combinations with alpha-1 blockers, tamoxifen, clomiphene, and flutamide.
The claims supplied do not claim dutasteride as a composition of matter.
The patent was historically listed in the Orange Book for Avodart.
The listed expiration date was June 19, 2016.
The patent is expired and does not currently block generic dutasteride entry.
Dutasteride is a small molecule; biosimilar litigation is not relevant.
Current commercial exposure comes primarily from generic price competition, product substitution, and manufacturing economics.

Frequently Asked Questions

Does U.S. Patent 5,846,976 cover finasteride?

No. The claims identify dutasteride by its specific chemical structure. They do not cover finasteride.

Does the patent cover dutasteride for prostate cancer?

Claim 2 expressly lists prostate cancer as an androgen-responsive or androgen-mediated condition. The claim’s enforceability ended when the patent expired.

Does claim 8 cover dutasteride plus flutamide alone?

No. Claim 8 depends on claim 6 and therefore requires tamoxifen as well as flutamide. It covers the narrower dutasteride-tamoxifen-flutamide combination.

Can a generic company sell dutasteride for male pattern baldness?

FDA approval depends on the proposed labeling and applicable regulatory requirements. Patent 5,846,976 no longer blocks the use because it expired, but a generic label still must comply with the ANDA framework and cannot rely on unsupported indications.

Are dutasteride metabolites or prodrugs covered by the patent?

Not expressly. The claims identify dutasteride and pharmaceutically acceptable solvates. A metabolite, prodrug, salt, polymorph, or derivative requires separate claim-construction and infringement analysis.

References

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
United States Patent and Trademark Office. (2024). Patent term calculator and patent term adjustment resources. USPTO.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and patent certifications under the Hatch-Waxman Act. FDA.
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. FDA.
U.S. Patent No. 5,846,976. (1998). Treatment of androgen responsive diseases with 4-aza steroids. United States Patent and Trademark Office.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0719278	⤷ Start Trial	300122	Netherlands	⤷ Start Trial
European Patent Office	0719278	⤷ Start Trial	SPC/GB03/018	United Kingdom	⤷ Start Trial
European Patent Office	0719278	⤷ Start Trial	PA2003007	Lithuania	⤷ Start Trial
European Patent Office	0719278	⤷ Start Trial	PA2003007,C0719278	Lithuania	⤷ Start Trial
European Patent Office	0719278	⤷ Start Trial	SPC009/2005	Ireland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,846,976

Summary for Patent: 5,846,976